Management Team

Guido BaechlerPresident and Chief Executive Officer
Guido Baechler has served as President and Chief Executive Officer of Singulex since 2013, bringing with him over two decades of experience working with emerging technologies in the life sciences and diagnostics industries. Guido joined Singulex in 2008, serving first as Vice President of Diagnostics and then as Senior Vice President of Operations. Previously, Guido worked at Roche in both the U.S. and Switzerland. He held executive and leadership positions at both Roche Diagnostics and Roche Molecular Diagnostics and gained managerial and functional expertise in research, development and marketing.
Guido holds a B.S. in Electrical Engineering from Fachhochschule Brugg-Windisch in Switzerland. He has completed a series of executive finance and management classes at the London School of Business and the Haas School of Business, University of California, Berkeley.

Jeffrey Bishop, Ph.D.Vice President, Research and Development
Jeff Bishop joined Singulex in 2013. Jeff has worked in the diagnostics industry for more than 13 years at Biosite, Inverness Medical Innovations and Alere. During this time, Jeff held various scientific and leadership positions within the R&D organization including Vice President of R&D for Point of Care platforms and Vice President of R&D for Drugs of Abuse platforms. Jeff has extensive experience working with biomarkers and has led the development of many drug and biomarker assays on numerous platforms across a wide range of disease states.
Jeff earned both an M.S. and a Ph.D. in Bioengineering from the University of California, San Diego and holds a B.S. in Chemical Engineering from Brigham Young University. He also holds an RAC certification in Regulatory Affairs.
Bob BrousseauVice President, Sales and Marketing
Bob Brousseau joined Singulex in 2015. He has 20 years of commercial leadership experience that includes sales, marketing, operations, and reimbursement. Most recently he was with Agendia as Executive Vice President of Global Sales. Prior to Agendia, he had leadership roles with Genoptix, Cypress Bioscience, Verus Pharmaceuticals, and Elan Pharmaceuticals. Bob has a rich history with cancer diagnostics and has been responsible for building several start-up commercial organizations.
Bob earned a B.A. in Finance from the University of Oklahoma and an M.B.A. from Southern Methodist University.
Byron ClendenenVice President, Human Resources
Byron Clendenen joined Singulex in 2014 and possesses 25 years of HR leadership experience. Previously, Byron served and led HR functions in diverse settings such as CollabNet, Inc., within the enterprise cloud development software tools & services space; Vpacket Communications within the VoIP telecom space; Integrated Systems within the embedded software space; and Toshiba America MRI within the medical diagnostic imaging space.
Byron has contributed in privately and publicly held settings, and has developed, managed, and refined HR functions and programs for start-ups as well as for mature, multi-national organizations.
Byron earned a B.A. in Psychology from the University of California, Berkeley, and an M.A. in Psychology from San Francisco State University. He additionally possesses SPHR certification.
Eric Hall, CFAChief Financial Officer
Eric Hall joined Singulex in 2016 as its Chief Financial Officer. He brings over 25 years’ experience as a CFO, COO, and President for private and public companies in a variety of industries. He has held life science company leadership positions in Valgenesis, Rodan+Fields, Pacific Fertility Center, Pharmatech Associates, and Systemix. Eric has extensive international experience and has served on several public and private boards of directors. Eric is also a partner of FLG Partners, LLC, since 2004.
Eric holds an M.B.A. in Finance from the Owen Graduate School of Management at Vanderbilt University and a B.A. in Economics from the University of California, Davis. He is a Chartered Financial Analyst and member of the CFA Institute.
Karen RichardsVice President, Regulatory Affairs and Quality Assurance
Karen Richards joined Singulex in 2012. Karen has worked in the in vitro diagnostics industry for over 30 years. She has held executive and leadership positions in Regulatory Affairs, Quality Assurance and Clinical Affairs at Tethys, Celera, Novartis Vaccines & Diagnostics and Beckman Coulter. Karen has led numerous in vitro diagnostics clinical trial programs and regulatory submissions, enabling successful market entry of products into the U.S., Europe, Asia and Latin America. In addition, Karen has built many quality systems in compliance with ISO 9001, 13485, and U.S. Quality System Regulations.
Karen holds a B.A. in Biological Sciences from the University of California, Santa Cruz and an RAC certification in Regulatory Affairs.
Patricia RyanCompliance Officer
Patricia Ryan joined Singulex in 2014, bringing over 20 years of experience focused on the internal control environment. Most recently, Patty served as the Latin American and Asia Pacific Regional Compliance Officer for Novartis Vaccines & Diagnostics as well as the U.S. Compliance Officer for the Diagnostics business, providing compliance support in all aspects of commercial activities. Patty joined Novartis Vaccines & Diagnostics as a Sarbanes- Oxley Compliance; Internal Controls Analyst. Patty also spent several years as a Corporate Internal Auditor for AT&T. Patty has worked for over a decade in local Public Accounting Firms in the San Francisco Bay area leading auditing and consulting service engagements.
Patty holds a B.S. in Business Administration with a concentration in Accounting from San Jose State University. She is a Certified Public Accountant and a Certified Internal Auditor.
Thomas Schlumpberger, Ph.D.Vice President, Diagnostics
Thomas Schlumpberger joined Singulex in 2015 with more than 16 years experience in the IVD, life science and pharmaceutical industry. Previously, Thomas held executive and leadership positions at Annai Systems, AliveCor, Invitae (f/k/a Locus Development), Epocal, Nektar and Affymetrix. Thomas had responsibility for commercialization and product launches at Invitae as Chief Commercial Officer and at Epocal as Sr VP of International Sales and Business Development. Before joining the healthcare industry, Thomas served as a consultant at McKinsey & Company.
Thomas earned a Ph.D. in Molecular & Cell Biology from the University of California, Berkeley and holds a M.S. in Electrical Engineering from the Technische Universitaet Muenchen.
Mark Stene, Ph.D.Senior Vice President, Operations
Mark Stene has over 25 years of experience managing and growing clinical laboratories and operations. Prior to joining Singulex, Mark held a number of key leadership roles at Quest Diagnostics, including Operations Director for the reference laboratories of both the Nichols Institute and Focus Diagnostics and Director of Laboratory Operations for the Southern California Business Unit. Mark also held roles of increasing responsibility in R&D, operations and general management at Endocrine Sciences and the successor companies of Esoterix and LabCorp.
Mark earned a Ph.D. in Experimental Pathology, an M.B.A. and a B.S. in Biochemistry from the University of California, Los Angeles. He is licensed in California as a Clinical Laboratory Scientist (CLS) and holds a Certification of Qualification (COQ) for the State of New York.
John Todd, Ph.D.Vice President, Clinical Research
John Todd joined Singulex in 2007 and has championed Singulex’s clinical programs to demonstrate the clinical utility of SMC™ for cardiovascular disease risk prediction and patient management. John has substantial diagnostics development experience, having developed products to address unmet clinical needs in numerous disease areas and successfully establishing their medical advantage.
Prior to joining Singulex, John held leadership and executive positions at numerous healthcare companies including Chiron Diagnostics, Bayer Diagnostics, Baxter Healthcare, NUGEN Technologies, Protogene Labs and ENZO Biochem. He has co-authored over 60 peer-reviewed publications and 90 scientific abstracts, been issued 15 patents and presented at over 100 biomedical scientific conferences. John has received 6 SBIR grants for the development and commercialization of diagnostic products.
John received a Ph.D. in Biochemistry and a B.S. in Biology from the University of Southern California, followed by post graduate training in Cell and Molecular Biology at the Sabatini Lab, New York University Medical Center.
Board of Directors

Guido BaechlerPresident and Chief Executive Officer
Guido Baechler has served as President and Chief Executive Officer of Singulex since 2013, bringing with him over two decades of experience working with emerging technologies in the life sciences and diagnostics industries. Guido joined Singulex in 2008, serving first as Vice President of Diagnostics and then as Senior Vice President of Operations. Previously, Guido worked at Roche in both the U.S. and Switzerland. He held executive and leadership positions at both Roche Diagnostics and Roche Molecular Diagnostics and gained managerial and functional expertise in research, development and marketing.
Guido holds a B.S. in Electrical Engineering from Fachhochschule Brugg-Windisch in Switzerland. He has completed a series of executive finance and management classes at the London School of Business and the Haas School of Business, University of California, Berkeley.
Heiner Dreismann, Ph.D.Lead Director
Heiner Dreismann, Ph.D. has been a member of our board of directors since June of 2007 and has over 26 years of experience in biotech and healthcare companies. Since May of 2008, Dr. Dreismann has served as Interim Chief Executive Officer of GeneNews Limited, a public diagnostics company. From 2001 until 2006, Dr. Dreismann served as President and Chief Executive Officer of Roche Molecular Systems, Inc., a division of Hoffmann-La Roche Ltd., or Roche, focused on clinical molecular diagnostics.
Before serving in these roles, he held various management positions in Roche, among them Head of Integration Office Diagnostics and Head of Global Business Development for Roche Diagnostics. Dr. Dreismann currently serves on the boards of directors of Ignyta, Inc., Myriad Genetics, Inc., Med BioGene Inc. and GeneNews Ltd., each a public company in the life sciences or healthcare diagnostics sectors. Dr. Dreismann received his M.A. in Biology and his Ph.D. in Microbiology / Molecular Biology both from Westfaelische Wilhelms University (The University of Münster) in Germany. Dr. Dreismann brings to our board of directors significant expertise in the biotech and healthcare sectors from both his advanced degree and from previous executive leadership positions. In addition, Dr. Dreismann’s experience as a Director of public life sciences companies provides the board of directors with valuable insights to assist in achieving our goals.
Carl L. Gordon, Ph.D., CFAGeneral Partner, OrbiMed and Co-Head, Private Equity
Carl Gordon, Ph.D., CFA has been a member of our board of directors since June of 2007. Dr. Gordon co-founded OrbiMed Advisors LLC, or OrbiMed, where he serves as a General Partner and Co-Head of Private Equity. He is experienced in both private equity and small-capitalization public equity investments. Prior to his experience at OrbiMed, Dr. Gordon was a senior biotechnology analyst at Mehta and Isaly, a pharmaceutical consulting firm and predecessor to OrbiMed, from 1995 to 1997. From 1993 to 1995, Dr. Gordon was a fellow at The Rockefeller University. He received his Ph.D. in Molecular Biology from the Massachusetts Institute of Technology and a bachelor’s degree from Harvard College.
From August 2009 until June 2012, Dr. Gordon also served on the board of directors of Complete Genomics, Inc., a life sciences company. As a venture capitalist focused on life science companies who sits on numerous boards, Dr. Gordon provides financial and operational expertise regarding our industry. In addition, Dr. Gordon provides substantial expertise in the particularly relevant scientific field of molecular biology, and his financial credentials are valuable toward his service on our audit committee.
Stephen L. Rose, CPA, CMADirector, Fisk Ventures, LLC
Steve Rose, CPA, CMA, has been a member of our board of directors since September, 2004. Mr. Rose, who has over 17 years of experience in venture investing, is Managing Director of Fisk Ventures, LLC, the venture investment company for H. Fisk Johnson, Ph.D., Chairman of the Board, Chairman and Chief Executive Officer of S.C. Johnson and Son Inc., or S.C. Johnson. In this capacity, Mr. Rose serves on the boards of several early stage technology-based companies. Mr. Rose previously held several positions with S.C. Johnson in both the United States and in Canada, including positions in strategic planning, new business and new product development, and financial and business management.
Mr. Rose has an Honors Bachelor of Commerce from McMaster University, and is also a Certified Management Accountant. As a venture capitalist with experience on the boards of several emerging companies, Mr. Rose provides the Singulex Board of Directors with insightful and relevant expertise in both finance and operations. In addition, his financial credentials and experience are of significant value in his service on our governance committee.
Carsten SchroederPresident Diagnostics Division, Grifols
Carsten Schroeder is President of the Grifols Diagnostic Division, a recognized leader in Transfusion Medicine. In this role, Carsten is responsible for all aspects of the Division’s global commercial operations, including leading its growth and innovation in Transfusion Medicine and Specialty Diagnostics. As a member of the Grifols Executive Committee, Carsten is also responsible for shaping the company’s overall strategy in Diagnostics. Based in San Francisco, Carsten has lived and worked in ten countries and is fluent in several languages. He holds an MBA from the European School of Management in Paris (ESCP) and a Bachelor of Arts in Economics from the University of Cologne in Germany.
Fred K. VogtPresident, FKV Enterprises, LLC
Fred Vogt has been a member of our board of directors since our incorporation in 2002. Mr. Vogt has 28 years of operations and manufacturing experience in the pharmaceutical industry, and he currently provides consulting services to senior management executives through FKV Enterprises LLC. From 1997 until 2000, Mr. Vogt served as a Senior Vice President of Specialty Chemicals at Tetra Technologies Inc., a chemical manufacturer.
Prior to this experience, he worked for 25 years for Mallinckrodt, Inc., a chemical and pharmaceutical company, in a variety of manufacturing and business positions. Mr. Vogt has a bachelor’s degree in Chemical Engineering, a master’s degree in Engineering Administration and Honorary Professional Chemical Engineering degree from the University of Missouri at Rolla.
Advisory Board

Richard L. Popp, M.D.Chairman
Richard L. Popp, M.D., has served as Chairman of the Singulex Medical Advisory Board since 2012. Dr. Popp is a Professor of Medicine (Emeritus) at Stanford University School of Medicine, where he has served in numerous academic and administrative positions since joining the Stanford faculty in 1971. He received his medical degree from Johns Hopkins School of Medicine, where he performed his internship and residency before completing further clinical and research training in cardiology at Indiana University Medical Center and Stanford University Hospital.
During his career, Dr. Popp has focused his research on non-invasive methods for diagnosis and treatment of cardiovascular disease, pioneering the development of cardiac ultrasound technology and contributing to the continuous improvement of ultrasonic diagnostic methods. The author of over 270 publications, Dr. Popp is a former President of the American College of Cardiology, The American Society of Echocardiography and The Association of University Cardiologists, and served as Chairman of the American Board of Internal Medicine’s (ABIM) Cardiovascular Diseases Subspecialty Board. Dr. Popp’s continuing interest in the development of technologies that will enhance patient care and potential outcomes, combined with his substantial breadth of experience and achievement in cardiovascular medicine, provides an invaluable contribution to our Medical Advisory Board.